Metabolic syndrome (MS) has been reported as a risk for cardiovascular events. The aim of the present cohort study is to investigate whether ACEi therapy reduces the rate of periprocedural myocardial injury (PPMI) after elective percutaneous coronary intervention (PCI) among patients with metabolic syndrome.

Inclusion Criteria:

1. metabolic syndrome
2. elective percutaneous coronary intervention with angiographically successful stent implantation

Exclusion Criteria:

1. acute coronary events
2. renal failure
3. needed the use of IV glycoprotein IIb/IIIa receptor inhibitors were excluded
4. left main coronary artery disease
5. chronic total occlusion
6. high levels of baseline CKMB or troponin
7. any contraindication of aspirin, clopidogrel or ACEi treatment

Metabolic syndorme (MS) was defined as the presence of 3 or more of these components:

1. high fasting glucose (fasting serum glucose ≥100 mg/dl or drug treatment for elevated blood glucose)
2. abdominal obesity (given as waist circumference >102 cm in men and >88 cm in women)
3. high blood pressure (>130/>85 mmHg or drug treatment for hypertension)
4. hypertriglyceridemia (serum triglycerides ≥150 mg/dl)
5. low high-density lipoprotein (HDL) cholesterol (<40 mg/dl in men and <50 mg/dl in women).